26-Dec-2025
No headlines found.
Business Wire (Tue, 16-Dec 1:00 AM ET)
PRNewswire (Thu, 11-Dec 10:00 AM ET)
Bicycle Therapeutics to Participate in the Jefferies London Healthcare Conference
Business Wire (Wed, 12-Nov 4:05 PM ET)
Bicycle Therapeutics Reports Recent Business Progress and Third Quarter 2025 Financial Results
Business Wire (Thu, 30-Oct 7:00 AM ET)
Bicycle Therapeutics PLC is a clinical-stage biopharmaceutical company developing a novel class of medicines which are referred to as Bicycles. The Bicycles are synthetic short peptides constrained to form two loops that stabilize their structural geometry. Its initial internal programs are focused on oncology indications with high unmet medical needs. The company's product candidate, BT1718, is a Bicycle Toxin Conjugate, or BTC. The company has two segments: the United Kingdom and the United States. It derives maximum revenue from United States.
Bicycle Therapeutics PLC - American Depositary Shares trades on the NASDAQ stock market under the symbol BCYC.
As of December 26, 2025, BCYC stock price declined to $6.82 with 153,649 million shares trading.
BCYC has a beta of 1.67, meaning it tends to be more sensitive to market movements. BCYC has a correlation of 0.26 to the broad based SPY ETF.
BCYC has a market cap of $472.67 million. This is considered a Small Cap stock.
Last quarter Bicycle Therapeutics PLC - American Depositary Shares reported $12 million in Revenue and -$.85 earnings per share. This beat revenue expectation by $3 million and exceeded earnings estimates by $.23.
In the last 3 years, BCYC traded as high as $31.91 and as low as $6.03.
The top ETF exchange traded funds that BCYC belongs to (by Net Assets): IBB, MSSM, SBIO, GWX, MEDI.
BCYC has underperformed the market in the last year with a price return of -53.3% while the SPY ETF gained +16.0%. BCYC has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -7.8% and -8.5%, respectively, while the SPY returned +4.6% and +1.5%, respectively.
BCYC support price is $6.72 and resistance is $7.26 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that BCYC shares will trade within this expected range on the day.
